Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Japan doubles areas under COVID curbs as cases set records

BY Reuters
— 5:01 AM ET 01/25/2022

TOKYO, Jan 25 (Reuters) - Japan expanded regions subject to tighter coronavirus curbs to cover 70% of the country on Tuesday, as the government tried to counter a record wave of COVID-19 cases caused by the Omicron variant.

The measures, already in force in 16 prefectures, will take effect in a further 18 including the western prefectures of Kyoto and Osaka and remain in place until the middle of next month.

Nationwide cases rose above 60,000 for the first time since the pandemic began, a tally by broadcaster Fuji TV showed on Tuesday, with the capital, Tokyo, posting 12,813 new cases while the region of Osaka reported 8,612, both records.

Economy minister Daishiro Yamagiwa told reporters the central government agreed to impose tougher counter-measures in 18 more regions in response to an increase of infections and hospital admissions driven by Omicron. A panel of health experts signed off on the plan earlier in the day.

The curbs will run from Thursday until Feb. 20, empowering regional governors to ask restaurants and bars to shorten their business hours and to stop serving alcohol.

The stricter measures come as the government is shifting its approach to handling the soaring number of cases.

The health ministry announced late on Monday it will allow doctors to diagnose those who have had close contact with a COVID-19 patient and who show symptoms as being infected without the need for a test, if deemed necessary by local governments.

The new policy will enable patients to get prompt treatment, said Chief Cabinet Secretary Hirokazu Matsuno.

"We're presenting a policy to expand the options available to patients," he said.

Managing COVID-19 without laboratory test confirmations is similar to how doctors fight influenza in areas where "the community burden is high", said Kazuaki Jindai, a physician and researcher at Tohoku University.

"The important thing is that some people will get sick eventually and we need to have a good monitoring system to make sure that they are safe. Not only by providing them hospitalization but also access to new oral medications."

Kyle Tattle, president of the Japanese arm of U.S. drugmaker Merck & Co INC. (MRK), told reporters the company was working to provide its COVID-19 oral pill, molnupiravir, as soon as possible.

The government would also weigh scientific data in considering shorter quarantines for people who have had close contact with COVID-19 patients, Kishida told a parliamentary debate. (Reporting by Rocky Swift, Satoshi Sugiyama and Ritsuko Shimizu Editing by Robert Birsel, Alexandra Hudson)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More MRK News

  • Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
    GlobeNewswire - 8:00 AM ET 01/04/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close